Form 4: LAVA Therapeutics CEO Sells Shares, Cancels Options

LAVA Therapeutics CEO Stephen A. Hurly disposed of 5,000 common shares and cancelled 335,100 share options under a pre-planned agreement.

Summary

• Stephen A. Hurly, Chief Executive Officer and Director of LAVA Therapeutics NV (LVTX), reported changes in his beneficial ownership.
• Disposed of 5,000 common shares on November 13, 2025, for $1.04 in cash per share plus one non-transferable contingent value right (CVR) per share.
• Cancelled 335,100 share options on November 13, 2025, which had an exercise price of $0.93.
• The cancellation of options resulted in cash equal to the excess of $1.04 over the $0.93 per share exercise price, multiplied by the total number of shares underlying the options, plus one CVR per share.
• These transactions were executed pursuant to a Purchase Agreement dated August 3, 2025, between LAVA Therapeutics NV and XOMA Royalty Corporation.
• The transactions were made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 3

Explanation: The sentiment is moderately negative due to significant insider selling by the CEO, even though it was pre-planned. Complete divestment of direct holdings by a key executive can raise concerns among investors regarding future company performance and management's alignment with shareholder interests.

Positives

• The transactions were executed under a Rule 10b5-1(c) plan, indicating a pre-planned sale rather than a reaction to recent events, which can mitigate some negative perceptions of insider selling.
• The CEO received cash and contingent value rights (CVRs) for the disposed shares and cancelled options, providing immediate liquidity and potential future value tied to specific contingencies.

Negatives

• Stephen A. Hurly, the CEO and a Director, disposed of all his directly owned common shares and cancelled all reported share options, significantly reducing his direct equity stake in the company.
• Significant insider selling by a key executive, even if pre-planned, can be perceived negatively by the market and may signal a lack of confidence in the company's future prospects.

Risks

• Market perception risk due to the complete divestment of direct equity holdings by the Chief Executive Officer, which could lead to a decline in investor confidence and potentially impact the company's share price.

Future Outlook

NA

Industry Context

This Form 4 filing details an insider transaction, which is specific to the reporting person and LAVA Therapeutics NV. It does not inherently provide broader industry trends or competitive insights, though significant insider selling can sometimes reflect internal views on company or industry prospects.

Related Party Transactions

• The disposal of shares and cancellation of options were executed pursuant to a Purchase Agreement dated August 3, 2025, between the Issuer (LAVA Therapeutics NV) and XOMA Royalty Corporation.

Stakeholder Impact

• Shareholders: May interpret the CEO's complete divestment of direct equity as a negative signal, potentially impacting investor confidence and the company's share price.
• Employees: No direct impact mentioned, but a decline in share price could affect the value of equity-based compensation.

Key Dates

Recommendation

The complete disposal of direct common shares and cancellation of all reported options by the Chief Executive Officer, Stephen A. Hurly, despite being pre-planned under a Rule 10b5-1 agreement, sends a strong negative signal to the market. Such a significant reduction in a key executive's direct equity stake can erode investor confidence and suggest a lack of long-term commitment or belief in the company's future prospects, warranting a 'sell' recommendation for investors sensitive to insider sentiment and management alignment.

Keywords

LAVA Therapeutics, LVTX, Stephen A. Hurly, Insider Trading, Form 4, SEC Filing, Share Sale, Option Cancellation, CEO, Director, XOMA Royalty Corporation, Contingent Value Right, Rule 10b5-1